[Innovative Concepts in Early Cancer Detection and Staging of Localized Prostate Cancer]

Overview

Journal Urologe A

Specialty Urology

Date 2005 Oct 26

PMID 16247635

Authors

L Rinnab

R Kufer

R E Hautmann

B G Volkmer

M Straub

N M Blumstein

H W Gottfried

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the most common malignancy in males. Men aged 50 years and older are recommended to undergo an annual digital rectal examination (DRE) and determination of prostate-specific antigen (PSA) in serum for early detection. Fortunately, disease-specific mortality continues to decline as a result of advances in screening, staging, and patient awareness. However, about 30% of men with a clinically organ-confined disease show evidence of extracapsular extension or seminal vesicle invasion on pathological analysis. Consequently, there is a need for more accurate diagnostic tools for planning tailored treatment. A variety of modern imaging techniques has been implemented in an attempt to obtain more precise staging, thereby allowing for more detailed counseling, and instituting optimum therapy. This review highlights developments in prostate cancer imaging that may improve staging and treatment planning for prostate cancer patients.

References

Loch T, Leuschner I, Genberg C, Weichert-Jacobsen K, Kuppers F, Retz M . [Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma]. Urologe A. 2000; 39(4):341-7. DOI: 10.1007/s001200050367. View

Garg S, Fortling B, Chadwick D, Robinson M, Hamdy F . Staging of prostate cancer using 3-dimensional transrectal ultrasound images: a pilot study. J Urol. 1999; 162(4):1318-21. View

Loch T . [Computerized supported transrectal ultrasound (C-TRUS) in the diagnosis of prostate cancer]. Urologe A. 2004; 43(11):1377-84. DOI: 10.1007/s00120-004-0710-7. View

Machtens S, Boerner A, Hofmann M, Knapp W, Jonas U . [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors]. Urologe A. 2004; 43(11):1397-409. DOI: 10.1007/s00120-004-0714-3. View

Folkman J, Watson K, Ingber D, Hanahan D . Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989; 339(6219):58-61. DOI: 10.1038/339058a0. View

Ellis W, Chetner M, Preston S, Brawer M . Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol. 1994; 152(5 Pt 1):1520-5. DOI: 10.1016/s0022-5347(17)32460-6. View

Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M . Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999; 36(1):31-5. DOI: 10.1159/000019923. View

DeGrado T, Coleman R, Wang S, Baldwin S, Orr M, Robertson C . Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001; 61(1):110-7. View

Hautzel H, Muller-Mattheis V, Herzog H, Roden W, Coenen H, Ackermann R . [The (11C) acetate positron emission tomography in prostatic carcinoma. New prospects in metabolic imaging]. Urologe A. 2003; 41(6):569-76. DOI: 10.1007/s00120-002-0244-9. View

10.

Halpern E, Rosenberg M, Gomella L . Prostate cancer: contrast-enhanced us for detection. Radiology. 2001; 219(1):219-25. DOI: 10.1148/radiology.219.1.r01ap21219. View

11.

Bogers H, Sedelaar J, Beerlage H, de la Rosette J, Debruyne F, Wijkstra H . Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. Urology. 1999; 54(1):97-104. DOI: 10.1016/s0090-4295(99)00040-0. View

12.

Schmid D, John H, Zweifel R, Cservenyak T, Westera G, Goerres G . Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005; 235(2):623-8. DOI: 10.1148/radiol.2352040494. View

13.

Oyama N, Miller T, Dehdashti F, Siegel B, Fischer K, Michalski J . 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003; 44(4):549-55. View

14.

de Jong I, Pruim J, Elsinga P, Vaalburg W, Mensink H . 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003; 44(1):32-8; discussion 38-9. DOI: 10.1016/s0302-2838(03)00207-0. View

15.

Tempany C, Rahmouni A, Epstein J, Walsh P, Zerhouni E . Invasion of the neurovascular bundle by prostate cancer: evaluation with MR imaging. Radiology. 1991; 181(1):107-12. DOI: 10.1148/radiology.181.1.1887017. View

16.

Presti Jr J, Hricak H, Narayan P, Shinohara K, White S, Carroll P . Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol. 1996; 166(1):103-8. DOI: 10.2214/ajr.166.1.8571856. View

17.

Norberg M, Egevad L, Holmberg L, Sparen P, Norlen B, Busch C . The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997; 50(4):562-6. DOI: 10.1016/S0090-4295(97)00306-3. View

18.

Leibovici D, Kamat A, Do K, Pettaway C, Ng C, Evans R . Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate. 2004; 62(1):101-4. DOI: 10.1002/pros.20127. View

19.

Brassell S, Rosner I, McLeod D . Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer. Curr Opin Urol. 2005; 15(3):163-6. DOI: 10.1097/01.mou.0000165549.94663.2d. View

20.

Smith Jr J, Scardino P, Resnick M, Hernandez A, Rose S, Egger M . Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol. 1997; 157(3):902-6. View